Updated 20/06/2026
A comprehensive analysis of more than 60,000 patients has revealed that people with coeliac disease face significantly higher risks of death, cardiovascular disease, and certain cancers compared to the general population. The study, published in The Lancet Regional Health – Americas, represents one of the largest investigations into long-term health outcomes for patients with coeliac disease and dermatitis herpetiformis.
Mortality and Disease Risk in Coeliac Disease Patients
Hazard ratios compared to matched controls, 2000-2021
mortality
disease
lymphoma
Source: The Lancet Regional Health – Americas, 2026 | Georgian Medical Journal News
Comprehensive Analysis of 60,000 Patients Reveals Health Disparities
Researchers from Columbia University and Karolinska Institute analysed data from 35,359 patients with coeliac disease and 25,563 patients with dermatitis herpetiformis, matched against control groups from the general population. The study, led by Dr. Benjamin Lebwohl at Columbia University Irving Medical Center, tracked patients for an average of 10.5 years using comprehensive health registries.
The findings demonstrate that coeliac disease patients face a 39% increased risk of death compared to matched controls, with dermatitis herpetiformis patients showing an even higher 41% increased mortality risk. “These results highlight the importance of comprehensive medical follow-up for patients with these conditions,” the authors noted in their analysis published in The Lancet Regional Health – Americas.
Cardiovascular Disease Risk Significantly Elevated
Both patient groups showed substantially higher risks of cardiovascular disease, with coeliac disease patients facing a 27% increased risk and dermatitis herpetiformis patients a 35% higher risk. Major adverse cardiovascular events (MACE) were particularly concerning, occurring 28% more frequently in coeliac disease patients compared to controls.
The World Health Organization identifies cardiovascular disease as the leading cause of death globally, making these findings particularly significant for clinical practice. The study’s methodology involved matching patients by age, sex, calendar year, and county of residence to ensure accurate risk assessment.
Cancer Patterns Differ Between Conditions
Cancer risk patterns revealed important distinctions between coeliac disease and dermatitis herpetiformis. Both conditions showed dramatically increased risks of non-Hodgkin lymphoma, with coeliac disease patients facing 2.38 times the normal risk and dermatitis herpetiformis patients showing an even more pronounced 3.36-fold increase according to the Lancet analysis.
Interestingly, coeliac disease patients showed increased risks of lung and liver cancers, while dermatitis herpetiformis patients had elevated risks of kidney cancer and melanoma. These findings suggest different underlying mechanisms may contribute to cancer development in each condition, warranting further investigation by researchers at institutions monitoring emerging clinical evidence.
Clinical Implications for Patient Management
The study’s large scale and comprehensive methodology provide robust evidence for enhanced surveillance protocols in coeliac disease and dermatitis herpetiformis patients. The research team utilised data from multiple Swedish national health registries, ensuring complete follow-up and minimising selection bias that has limited previous studies.
For clinicians managing these patients, the findings support implementing regular cardiovascular risk assessments and cancer screening protocols beyond standard care guidelines. The National Institutes of Health emphasises the importance of personalised screening approaches for high-risk patient populations, which these results clearly support.
Patients with coeliac disease had a 39% increased mortality risk and 2.38 times higher risk of non-Hodgkin lymphoma compared to matched controls from the general population.
— Dr. Benjamin Lebwohl, Columbia University Irving Medical Center (The Lancet Regional Health – Americas, 2026)
Key takeaways
- Coeliac disease and dermatitis herpetiformis patients face significantly higher mortality risks (39% and 41% respectively) compared to the general population
- Both conditions are associated with increased cardiovascular disease risk, with MACE occurring 28-35% more frequently
- Non-Hodgkin lymphoma risk is dramatically elevated in both conditions, particularly dermatitis herpetiformis (3.36-fold increase)
- Cancer risk patterns differ between conditions, suggesting distinct underlying mechanisms
- Enhanced surveillance protocols may be warranted for comprehensive patient management
Frequently asked questions
Does following a gluten-free diet reduce these health risks?
The study did not specifically examine the impact of gluten-free diet adherence on long-term outcomes. However, strict gluten-free diet compliance is the established treatment for both conditions and may influence disease complications over time.
Why is non-Hodgkin lymphoma risk so much higher in these patients?
Both coeliac disease and dermatitis herpetiformis involve chronic immune system activation and inflammation, which may contribute to lymphoma development. The exact mechanisms require further research to fully understand.
Should patients with these conditions receive different medical monitoring?
The findings suggest enhanced cardiovascular risk assessment and cancer surveillance may be beneficial, though specific clinical guidelines have not yet been updated based on these results. Patients should discuss personalised monitoring plans with their healthcare providers.
These findings underscore the importance of recognising coeliac disease and dermatitis herpetiformis as systemic conditions requiring comprehensive medical management beyond dietary intervention. As healthcare systems adapt to evidence-based approaches for managing these patients, the study provides crucial data for developing targeted surveillance and prevention strategies. The research team continues investigating potential mechanisms underlying these associations to inform future therapeutic approaches.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
